CHENGDU, China — Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled “BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR...
Latest News
KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program...
SOUTH SAN FRANCISCO, Calif. – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors. “Micki’s addition to the board is instrumental as we continue to evaluate the...
NIJMEGEN, Netherlands — Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced that the United States Patent and Trademark Office and the European Patent Office have granted patents covering the use of Khondrion’s lead compound sonlicromanol as an [mPGES-1 inhibiting] anti-inflammatory agent. Sonlicromanol...
For more than two years, Tobey Miller hasn’t been able to read her baby bedtime stories and kiss him good night. The only home he has ever known has been a room at Cardinal Glennon Children’s Medical Center, more than two hours away from her. A rare kidney disease —...
Osaka, Japan – Guillain–Barré syndrome (GBS), a rare immune-mediated peripheral neuropathy that can cause permanent disability and even death and be quite severe to manage. In this acute disorder, which typically triggers after a respiratory or gastrointestinal tract infection, the body’s immune system attacks its own peripheral nerves, damaging the...
ESCONDIDO — A five-year-old kindergarten student at Pioneer Elementary School is recovering from pertussis, or whooping cough, health officials said Tuesday. The child developed the bacterial disease even after receiving the recommended five-part course of vaccinations, officials said. County Public Heath Officer Wilma Wooten explained that while the whooping cough...
SEATTLE, Washington — Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, today announced two major achievements in its gene therapy program: a commitment by the Jain Foundation to invest up to $1.1 million based on the achievement of certain milestones to support critical preclinical studies, and...
SEATTLE, WA — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking...
SAN DIEGO – Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D., co-leading...